Tag: Sotagliflozin

Both Inpefa and Jardiance are part of the SGLT inhibitor class, but a key pharmacological distinction lies in their targets. The short answer to the question, 'Is Inpefa the same as Jardiance?' is no, but a deeper look reveals why these medications, despite sharing some benefits, are distinct.

In 2023, the FDA approved sotagliflozin, marketed as Inpefa, for reducing the risk of cardiovascular death and hospitalization in adults with heart failure. Understanding what type of drug is sotagliflozin is key to recognizing its unique pharmacological profile.

Research indicates that sotagliflozin, a dual SGLT1/SGLT2 inhibitor, may offer specific cardiovascular benefits, such as in post-worsening heart failure, not seen with the SGLT2-selective dapagliflozin. The question of is sotagliflozin better than dapagliflozin depends on the patient's condition, particularly their type of diabetes and specific cardiac risk factors.

In late 2024, the FDA's advisory committee delivered an 11-3 vote against approving sotagliflozin (brand name Zynquista) for type 1 diabetes patients with chronic kidney disease. This decision marked the second major setback for the drug in this indication, as the FDA rejected sotagliflozin once again over persistent and unmitigated concerns about a heightened risk of diabetic ketoacidosis (DKA).

The sodium-glucose cotransporter 1 (SGLT1) protein is largely responsible for the absorption of dietary glucose from the small intestine, but it also plays a compensatory role in the kidneys. SGLT1 drugs are pharmacological agents designed to inhibit the action of this transporter, offering new strategies for managing glucose levels in various metabolic and cardiovascular conditions.